See more : Parrot SA (PABSA.PA) Income Statement Analysis – Financial Results
Complete financial analysis of PT Pyridam Farma Tbk (PYFA.JK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PT Pyridam Farma Tbk, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- bpost NV/SA (BPOST.SW) Income Statement Analysis – Financial Results
- goeasy Ltd. (EHMEF) Income Statement Analysis – Financial Results
- Costco Wholesale Corporation (0I47.L) Income Statement Analysis – Financial Results
- Toast, Inc. (TOST) Income Statement Analysis – Financial Results
- Yuanda China Holdings Limited (2789.HK) Income Statement Analysis – Financial Results
PT Pyridam Farma Tbk (PYFA.JK)
About PT Pyridam Farma Tbk
PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, antibiotics, vitamins, supplements, and traditional herbal care products in Indonesia. The company operates in two segments, Pharmaceutical Products and Toll Manufacturing Services; and Medical Device Products. It offers medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR extraction kit and extractor machine, speciment bag, sterile container, and tube stopper. The company also provides skin care products comprising Arosa gel, A-Stark Gel, Hymen gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb gel; products in the areas of alimentary t. and metabolism, blood and blood forming organs, cardiovascular system, dermatologicals, G.U. system and sex hormones, systemic corticosteroids, systemic antibacterial, sensory organs, as well as musculo-skeletal, nervous, and respiratory systems; and supplements and other preventive consumer health products with energy drinks and healthy ready-to-drink products. In addition, it engages in the research and development on biotechnology, life, and medical science. The company was founded in 1976 and is headquartered in Jakarta, Indonesia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 702.07B | 715.43B | 630.53B | 277.40B | 247.11B | 250.45B | 223.00B | 216.95B | 217.84B | 222.30B | 192.56B | 176.73B | 151.09B | 140.86B | 132.00B | 119.58B | 86.64B | 61.34B | 39.64B |
| Cost of Revenue | 406.75B | 464.58B | 385.95B | 113.51B | 106.91B | 99.34B | 88.03B | 81.64B | 79.86B | 80.96B | 62.13B | 61.06B | 49.50B | 51.08B | 47.76B | 41.21B | 31.01B | 21.10B | 16.24B |
| Gross Profit | 295.32B | 250.84B | 244.58B | 163.89B | 140.20B | 151.10B | 134.98B | 135.32B | 137.98B | 141.34B | 130.43B | 115.67B | 101.59B | 89.78B | 84.24B | 78.37B | 55.63B | 40.24B | 23.40B |
| Gross Profit Ratio | 42.06% | 35.06% | 38.79% | 59.08% | 56.74% | 60.33% | 60.53% | 62.37% | 63.34% | 63.58% | 67.74% | 65.45% | 67.24% | 63.73% | 63.82% | 65.53% | 64.21% | 65.61% | 59.04% |
| Research & Development | 17.77B | 11.28B | 573.44M | 0.00 | 5.65B | 853.19M | 2.31B | 1.19B | 3.18B | 1.36B | 3.26B | 1.46B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 31.28B | 27.12B | 20.59B | 11.89B | 10.07B | 8.70B | 8.54B | 8.25B | 9.50B | 9.29B | 6.35B | 24.30B | 31.09B | 24.08B | 19.17B | 14.61B | 10.17B | 8.63B | 6.48B |
| Selling & Marketing | 117.06B | 99.28B | 96.74B | 61.39B | 56.92B | 70.43B | 55.74B | 65.56B | 68.93B | 76.16B | 70.35B | 82.48B | 63.50B | 60.04B | 58.24B | 57.60B | 41.30B | 27.57B | 14.13B |
| SG&A | 148.35B | 126.40B | 117.33B | 73.28B | 66.99B | 79.13B | 64.28B | 73.81B | 78.43B | 85.44B | 76.70B | 106.78B | 94.59B | 84.12B | 77.41B | 72.21B | 51.47B | 36.20B | 20.61B |
| Other Expenses | 127.32B | 117.57B | 75.56B | 59.21B | 62.29B | 58.43B | 59.25B | 51.68B | -1.20B | -2.61B | -2.45B | 833.39M | 282.38M | 1.23B | 206.14M | -623.44M | 460.25M | 227.41M | 57.76M |
| Operating Expenses | 293.44B | 255.26B | 193.47B | 132.49B | 129.28B | 137.57B | 123.53B | 125.49B | 127.44B | 131.36B | 118.25B | 106.78B | 94.59B | 84.12B | 77.41B | 72.21B | 51.47B | 36.20B | 20.61B |
| Cost & Expenses | 700.19B | 719.84B | 579.42B | 246.00B | 236.19B | 236.91B | 211.56B | 207.12B | 207.29B | 212.32B | 180.38B | 167.83B | 144.09B | 135.20B | 125.17B | 113.42B | 82.48B | 57.30B | 36.85B |
| Interest Income | 1.37B | 291.61B | 299.17M | 63.38M | 23.25M | 14.30M | 6.00M | 4.52M | 5.86M | 7.09M | 10.45M | 29.31M | 65.26M | 10.33M | 10.85M | 31.96M | 2.40M | 621.40K | 2.59M |
| Interest Expense | 86.50B | 79.46B | 41.93B | 2.15B | 2.53B | 2.76B | 2.37B | 3.18B | 5.26B | 5.73B | 3.00B | 1.88B | 991.43M | 1.34B | 1.96B | 1.81B | 1.93B | 1.55B | 858.23M |
| Depreciation & Amortization | 57.45B | 71.25B | 31.54B | 9.07B | 7.42B | 7.30B | 8.62B | 9.18B | 2.90B | 3.76B | 3.22B | 661.26M | 347.64M | 1.32B | 564.54M | -703.55M | 395.61M | 336.79M | 10.14M |
| EBITDA | 60.70B | 421.42B | 83.74B | 41.28B | 22.72B | 21.82B | 20.68B | 19.70B | 12.72B | 13.70B | 14.72B | 16.06B | 8.08B | 6.98B | 7.39B | 5.45B | 4.56B | 4.38B | 2.80B |
| EBITDA Ratio | 8.65% | 41.15% | 9.31% | 12.02% | 6.18% | 5.94% | 6.36% | 5.70% | 5.69% | 6.02% | 7.48% | 5.41% | 4.87% | 4.96% | 5.60% | 4.56% | 5.26% | 7.13% | 7.07% |
| Operating Income | 1.88B | 345.86B | 51.90B | 32.14B | 15.28B | 14.51B | 12.06B | 10.52B | 10.14B | 10.19B | 8.50B | 8.90B | 7.00B | 5.66B | 6.83B | 6.16B | 4.16B | 4.04B | 2.79B |
| Operating Income Ratio | 0.27% | 48.34% | 8.23% | 11.59% | 6.18% | 5.79% | 5.41% | 4.85% | 4.65% | 4.59% | 4.41% | 5.03% | 4.64% | 4.02% | 5.17% | 5.15% | 4.80% | 6.59% | 7.05% |
| Total Other Income/Expenses | -85.13B | -82.78B | -43.08B | -2.50B | -2.76B | -3.19B | -2.46B | -3.47B | -5.58B | -5.98B | 0.00 | -926.11M | 80.77M | -20.22M | -1.40B | -2.51B | -1.54B | -1.22B | -848.09M |
| Income Before Tax | -83.25B | 263.08B | 8.81B | 29.64B | 12.52B | 11.32B | 9.60B | 7.05B | 4.55B | 4.21B | 8.50B | 7.97B | 7.09B | 5.64B | 5.43B | 3.65B | 2.62B | 2.82B | 1.95B |
| Income Before Tax Ratio | -11.86% | 36.77% | 1.40% | 10.69% | 5.07% | 4.52% | 4.30% | 3.25% | 2.09% | 1.89% | 4.41% | 4.51% | 4.69% | 4.00% | 4.11% | 3.05% | 3.03% | 4.60% | 4.91% |
| Income Tax Expense | 1.98B | -12.39B | 3.33B | 7.54B | 3.18B | 2.87B | 2.47B | 1.91B | 1.47B | 1.55B | 2.30B | 2.66B | 1.91B | 1.44B | 1.66B | 1.34B | 880.96M | 1.09B | 616.64M |
| Net Income | -85.22B | 275.24B | 5.48B | 22.10B | 9.34B | 8.45B | 7.13B | 5.15B | 3.09B | 2.66B | 6.20B | 5.31B | 5.17B | 4.20B | 3.77B | 2.31B | 1.74B | 1.73B | 1.33B |
| Net Income Ratio | -12.14% | 38.47% | 0.87% | 7.97% | 3.78% | 3.37% | 3.20% | 2.37% | 1.42% | 1.20% | 3.22% | 3.00% | 3.42% | 2.98% | 2.86% | 1.93% | 2.01% | 2.82% | 3.35% |
| EPS | -34.20 | 110.44 | 2.20 | 8.87 | 3.75 | 3.16 | 13.32 | 9.62 | 5.77 | 5.58 | 11.58 | 9.92 | 9.67 | 7.85 | 7.05 | 4.32 | 3.26 | 3.23 | 2.48 |
| EPS Diluted | -34.20 | 110.44 | 2.20 | 8.87 | 3.75 | 3.16 | 13.32 | 9.62 | 5.77 | 5.58 | 11.58 | 9.92 | 9.67 | 7.85 | 7.05 | 4.32 | 3.26 | 3.23 | 2.48 |
| Weighted Avg Shares Out | 2.49B | 2.49B | 2.49B | 2.49B | 2.49B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B |
| Weighted Avg Shares Out (Dil) | 2.49B | 2.49B | 2.49B | 2.49B | 2.49B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B | 2.68B |
Source: https://incomestatements.info
Category: Stock Reports